.jpg)
L'UMR-S 1144 change de nom en 2025 à l'occasion du nouveau contrat quinquennal (2025-2029) et devient "Optimisation Thérapeutique en Neuropharmacologie". Elle est située à la Faculté de Pharmacie de Paris (75006).
Organisée en quatre équipes, l'UMR-S 1144 est membre de la Fondation FondaMental.
Lithium is the first-line mood stabilizer for the treatment of patients with bipolar disorder. However, its mechanisms of action and transport across the blood-brain barrier remain poorly understood. The contribution of lithium-7 magnetic resonance imaging (7Li MRI) to investigate brain lithium distribution remains limited because of the modest sensitivity of the lithium nucleus and the expected low bra...
Opioids are widely used in pain management whose effects are due to binding to classical opioid receptors and/or Toll-like receptors (TLR) present at the central nervous system (CNS). At the blood-brain barrier (BBB), several influx and/or efflux transporters are expressed, such as the ATP-binding cassette (ABC) P-glycoprotein (P-gp, ABCB1), Breast Cancer Resistance Protein (BCRP, ABCG2) and multidrug resistance-asso...
OBJECTIVE: To identify risk factors for suicide attempts (SA) in individuals commencing treatment for a manic or mixed episode. METHOD: A total of 3390 manic or mixed cases with bipolar disorder (BD) type I recruited from 14 European countries were included in a prospective, 2-year observational study. Poisson regression models were used to identify individual and treatment factors associated with ...
The Science and Practice of Lithium Therapy by Gin S Mahli, Marc Masson, Frank Bellivier (Eds). Springer, 2017. ▶ Evidence-based guide to the clinical prescription of lithium ▶ Explains mechanisms of action and their significance ▶ Discusses indications, side effects, and monitoring ▶ Addresses the myths and concerns regarding lithium use This book prov...
Drugs able to treat both nociceptive and neuropathic pain effectively without major side effects are lacking. We developed a bifunctional peptide-based hybrid (KGNOP1) that structurally combines a mu-opioid receptor agonist (KGOP1) with antinociceptive activity and a weak nociceptin receptor antagonist (KGNOP3) with anti-neuropathic pain activity. We investigated KGNOP1-related b...
OBJECTIVES: We examine if the lithium response is associated with changes in core clock genes expressions. METHODS: The effect of a therapeutic concentration of lithium (1mM) on the expression levels of 17 circadian genes, was examined in lymphoblastoid cell lines (LCLs) derived from two well-characterized groups of BD patients, defined as lithium non-responders (NR, n = 20) or exce...
